Background: Pediatric patients undergoing liver transplant are at significant risk for bleeding and thrombotic complications due to the complex nature of rebalanced hemostasis in patients with liver disease.
INTRODUCTION
Pediatric patients undergoing liver transplant are at risk for significant bleeding and thrombotic complications. Studies in both pediatric and adult cohorts estimate an incidence of thrombotic events in up to 26% of cases. [1] [2] [3] [4] [5] [6] [7] [8] [9] Hepatic artery and portal vein thrombosis (PVT) are reported at rates of 5-15% in pediatric cohorts, which is three to four times the incidence in adults. 2, [5] [6] [7] [8] [9] [10] [11] Bleeding estimates are harder to quantify given variability in the definition of major bleeding, but Abbreviations: aPTT, activated partial thromboplastin time; CNS, central nervous system; EMR, electronic medical record; HAT, hepatic artery thrombosis; INR, international normalized ratio; pRBC, packed red blood cell; PT, prothrombin time; PVT, portal vein thrombosis; ROTEM, rotational thromboelastometry; TEG, thromboelastography range from approximately 5 to 9%. [12] [13] [14] The contribution of bleeding to morbidity is difficult to quantify, but thrombotic complications are known to reduce graft survival and contribute significantly to adverse outcomes, with mortality rates approaching 50% in those with hepatic artery thrombosis. 6, 9, 15, 16 The frequency and severity of bleeding and thrombotic complications in the liver transplant patient reflects the complicated balance of pro-and anticoagulant factors in patients with liver disease. The liver plays a key role in hemostasis, because it synthesizes the majority of proteins involved in clot stabilization and fibrinolysis. Although many of these factors are altered by liver disease, under normal circumstances these pro-and antithrombotic factors roughly balance each other out, leading to a relatively stable hemostatic equilibrium.
This concept has become known as "rebalanced hemostasis" in newly emerging literature on liver disease and transplantation. [17] [18] [19] This precarious state of delicately balanced pro-and anticoagulant factors is easily perturbed. Any invasive procedure or insult can disrupt the equilibrium. The extraordinary changes in vascular integrity, blood flow, and perfusion that occur with liver transplant can tip the pendulum even further. These disturbances may lead either to bleeding or thrombosis, but the direction in which this balance tips is not well predicted by our current laboratory tools. [20] [21] [22] [23] Despite prolongation of standard coagulation assays, such as the prothrombin time (PT) and activated partial thromboplastin time (aPTT), there is growing evidence that a pro-thrombotic state exists in many pediatric patients for up to several weeks posttransplant. [24] [25] [26] Due in part to a dearth of prognostic assays to accurately predict bleeding and thrombotic risk, there is no consensus on optimal posttransplant medical management. 15, 27 In addition to defining the incidence and nature of bleeding and thrombotic complications in pediatric patients undergoing liver and multivisceral transplant at Duke University Medical Center, this project also sought to identify patient, laboratory, or management factors that were associated with an increase in these complications.
METHODS

Study design and setting
We identified pediatric patients (birth to 18 years) who had undergone liver or multivisceral (combined liver, pancreas, and small bowel) transplant at Duke University Medical Center between January 1, 2009 and December 31, 2015.
Using the electronic medical record (EMR), we abstracted information from 30 days pre-to 90 days posttransplant (defined as the peritransplant period). EMR information was cross-referenced with documentation from the Organ Transplant Tracking Record and the Unet SM online database developed by United Network for Organ Sharing. We collected clinical information including adverse outcomes. We also collected data on blood products and hemostatic agents given between 30 days pre-and 30 days posttransplant.
We recorded the following clinical laboratory values during the peritransplant period: hemoglobin, platelet count, PT/international normalized ratio (INR), aPTT, fibrinogen, D-dimer, antithrombin activity, protein C activity, protein S activity, rotational thromboelastometry (ROTEM), thromboelastography (TEG), creatinine, aspartate transaminase, alanine transaminase, direct bilirubin, and indirect bilirubin. This study was approved by the Duke University Institutional Review Board (Pro00067233) with a waiver of informed consent and HIPAA authorization.
Outcomes and definitions
Thrombotic events were defined as any documented thrombus by imaging or clinical diagnosis made by direct observation during a surgical procedure. This included both venous and arterial thromboembolic events. Patients were screened for hepatic thrombosis regularly with liver Doppler ultrasound during the first week postoperatively, with confirmatory imaging based on identified clinical or imaging concerns.
Major bleeding events were defined as surgical bleeding requiring reoperation, central nervous system (CNS) bleeding, or anatomic bleeding (bleeding with identifiable hematoma requiring transfusion but not requiring surgical intervention). Intraoperative blood loss resulting in a >3 g/dl drop in hemoglobin occurred in 78% of cases.
Therefore, we did not include this definition as a major bleeding event for subsequent analyses.
Statistical analysis
Data were entered into a RedCap Database and analyzed using a statistical software package (SAS, Cary, NC) with the assistance of statistical support from the Duke Clinical Research Institute. Categorical variables were summarized as counts and percentages and continuous variables as median with minimum and maximum. Potential predictive risk factors of interest for bleeding and thrombosis were similarly summarized by event (bleeding or thrombosis) or no event, and with odds ratios with 95% confidence intervals using univariable logistic regression. Due to the rarity of liver transplant in the pediatric population, the sample size used was the largest feasible and included all of the transplant cases during the defined time period. The sample size was not large enough to compensate for multiple comparisons in the analysis due to the limitations on sample size. Table 1 . Patients in the "other" category included patients with acute hepatic failure or cirrhosis without identifiable etiology. Two patients were also included in the cohort who had been transplanted before the study period and required retransplantation.
RESULTS
Cohort demographics
Transplant characteristics and outcomes
Transplant characteristics are given in Table 2 . Just over 10% of cases were multivisceral transplants. Nearly a quarter of cases (22.8%) required a repeat operation for a bleeding or thrombotic complication.
Within the follow-up period, there were 10 retransplantations across eight separate recipients, with two patients requiring a third transplant. Three additional patients were listed for retransplantation but did not survive to receive a new organ. Five of these 10 retransplant procedures were for vascular thrombosis. All thrombotic events leading to retransplantation were hepatic artery thrombosis or combined hepatic artery and PVT, and all occurred within 30 days of initial transplant ( Table 2 ).
Overall survival in the cohort was 90.2% with a median followup time of 3.6 years (0.67-7.42 years). Four patients died within 30
TA B L E 1 Cohort demographics
Characteristic
All patients (N = 82) days of transplant for a 30-day mortality of 4.9%. Three of these four transplant-related deaths were due to vascular thrombosis. All three patients had both hepatic artery and portal vein thromboses leading to graft failure and all died within 8 days of transplant. The fourth patient died from complications of adenoviral pneumonia. The remaining patient deaths beyond 30 days were from infection, anoxia, cardiorespiratory arrest, and recurrent hepatocellular carcinoma (Table 2 ).
Bleeding and thrombotic complications
Overall in our cohort, there were 24 bleeding events in 19 transplants (incidence of 20.7%) ( Table 3 ). The majority of bleeding events were surgical (79.2%) requiring a repeat operation. There were three CNS bleeding events, and although these contributed to morbidity, none led directly to patient death. The majority of major bleeding events occurred within the first 7 days posttransplant (62.5%, N = 15 events).
There were 30 thrombotic events in 23 transplants in our cohort (incidence of 25%) ( Table 4) . Hepatic artery thrombosis (HAT) was the most common thrombotic event (occurring in 12% of transplants)
TA B L E 2 Transplant characteristics and outcomes
Characteristic All transplants (N = 92)
Type of transplant 
Practices and outcomes by year
TA B L E 3 Bleeding complications
All transplants (N = 92) 
Laboratory testing
Complete blood count, fibrinogen, and standard coagulation assays (PT/INR and aPTT) were measured frequently in all transplant recipients, with the majority having at least one measurement at each of the 12 time periods evaluated. Antithrombin activity was measured in 40.2% of transplants, with 95% of the measurements after 2012. Protein C and Protein S activity were only measured in 12% of transplants.
Viscoelastic testing (with TEG or ROTEM) was performed in 26.1% of transplants and over half (14 cases, 58.3%) since 2013.
Transfusion
The median number of blood product transfusions (defined as 1 standard unit or 1 episode of weight-based transfusion) per transplant 
Antithrombotic management
The majority of cases (92.4%) received postoperative antiplatelet prophylaxis with aspirin, typically for a period of about 3 months (Supplementary Table S1 ). Unfractionated heparin was used postoperatively in 48 transplants (52.2%), with 37 initiated for prophylaxis and 11 for treatment after a pre-or posttransplant thrombotic event. Over 80% of patients were discharged on either an antiplatelet or anticoagulant medication, with aspirin utilized in most cases. Enoxaparin or warfarin, frequently in combination with aspirin, was used in some cases (Supplementary Table S1 ).
Factors associated with bleeding or thrombosis
Univariable regression analysis was utilized to determine which clinical factors were associated with increased odds for bleeding or (Table 5 ). This could be confounded that patients perceived to have increased risk for bleeding did not receive prophylactic aspirin. Factors associated with increased risk of thrombosis also included a history of prior gastrointestinal surgery and a low postoperative fibrinogen. The use of prophylactic aspirin was associated with decreased thrombosis (Table 5) . Stratification based on dose of aspirin was not performed, but all patients received weight-based dosing as outlined in Figure 1 .
TA B L E 4 Thrombotic complications
All transplants (N = 92)
We examined several other patient, surgical, and laboratory variables ( Table 5 ) and found that none were predictive of bleeding or thrombosis. Intraoperative transfusions were not predictive of events and patients on prophylactic heparin were no more likely to require transfusion than those who were not anticoagulated (P = 0.531). However, the median number of transfusions given in the first 3 days posttransplant was higher in the transplants with bleeding (P < 0.001),
those with thrombosis (P = 0.022), and in transplants with both types of event (P = 0.046).
DISCUSSION
In our cohort of pediatric patients who underwent liver and multivisceral transplant, we observed a slightly higher incidence of both hepatic artery thrombosis (12%) and portal venous thrombosis (8.7%) compared to 1.35-16% in prior pediatric studies. [2] [3] [4] [5] [6] [8] [9] [10] [11] [12] [13] 30 The incidence of bleeding in our cohort was also higher than what has been reported previously (20.7% vs. 5-15%), [11] [12] [13] 30 but bleeding is reported inconsistently in prior cohorts and definitions vary, making the comparison difficult. Despite bleeding and thrombosis being similarly frequent events in our cohort, only thrombotic complications were associated with patient mortality. In contrast, bleeding tended to be more easily managed with transfusion or reoperation, with none requiring retransplantation or resulting in patient death.
Our 30-day survival rate was 95% and 1-year survival rate was 93%, which is in line with survival data from other studies. 4, 11, 12, 30, 31 Of the four deaths within 30 days of transplant, three were due to vascular thrombosis.
Overall our cohort was similar to other recent studies in terms of demographics, surgical era, and indications for transplant, but there were some key differences that may account for our higher rates of thrombosis and bleeding (Supplementary Tables S2 and S3 ). Overall, our population was much younger, with a median age of 15.5 months versus 1-7 years in most other groups. 4,9,30,31 The smaller vessel Table S3 ). These Along with this trend toward increased bleeding, we have seen an increase in transfusion. Transfusion during liver transplant in adults has been associated with many adverse outcomes and in general, many centers are moving toward minimizing transfusion in these patients. 28, [33] [34] [35] Multiple prior studies have shown negative consequences of excessive transfusion. Transfusion of pRBCs intraoperatively is a predictor of postoperative mortality in liver transplantation, 35, 36 transfusion of fresh frozen plasma has been associated with increased incidence of hepatic artery thrombosis, 7, 15 and platelet transfusion is also associated with poor outcomes. 28 In this cohort, a higher median number of transfusions in the first 3 days postoperatively was associated with both bleeding and thrombotic complications. The best thresholds for transfusion are not known in this population, in part due to our inability to predict which patients will have bleeding. Improvements in our ability to predict patients at risk for thrombosis or bleeding may improve our ability to decrease transfusion exposure.
TA B L E 5 Factors predictive of bleeding or thrombotic complications
Our assessment of some of the commonly used coagulation assays, including PT/INR, aPTT, and fibrinogen levels, demonstrated that these tests were poorly predictive of adverse events. Abnormalities in the PT and aPTT reflect the deficiencies in procoagulant proteins' production in patients with liver disease, 22 but they do not take into account the delicate balance of pro-and antithrombotic factors seen in patients with liver disease. 23 The PT and INR do track with overall severity and prognosis of liver disease, but they do not necessarily predict adverse events.
Fibrinogen is an appealing marker to follow as a proxy for bleeding risk because patients with liver disease are known to have both hyperfibrinolysis 37 and decreased fibrinolytic capacity. 38 Optimal levels at which either bleeding risk or thrombotic risk increases are not known. 22 In our cohort, a postoperative minimum fibrinogen of ≤75 mg/dl was associated with both increased bleeding and increased thrombosis. This makes it a poor predictive tool to distinguish risk of the two types of events. Additionally, the association of low fibrinogen with thrombosis may be due to confounding from transfusion to correct hypofibrinogenemia or it may simply be a reflection of a sicker patient population. It is also likely that these changes are dynamic with major differences in the fibrinolytic system during the anhepatic, reperfusion, and recovery phases of transplant. 39 As might be expected in patients with severe thrombocytopenia, patients in our cohort with platelet counts <50 × 10 9 /l intraoperatively and postoperatively had more bleeding. Thrombocytopenia is multifactorial in patients with liver disease. Despite this quantitative platelet defect, patients in liver failure with platelet counts as low as 50 × 10 9 /l have been shown to have adequate thrombin generation. 40 This may offer some protection from spontaneous bleeding but may not be sufficient for major surgical intervention. The platelet count is only indicative of overall platelet numbers, but says nothing about platelet function or activity. Activation of platelets and release of endothelial factors may contribute significantly to at least local hypercoagulability, but we did not observe any relationship between the platelet counts and risk for thrombosis.
Because of the inability of standard coagulation assays to give an accurate picture of the rebalanced hemostasis present in patients with liver disease, there is a need for alternative assays to help guide management. Alternative and global hemostasis assays are being utilized with increasing frequency in the transplant setting to try to better capture the rebalanced hemostasis present in patients with liver disease. 17, 18, [41] [42] [43] Recently, there have been several studies showing decreased transfusion requirements using viscoelastic testing during transplantation in adult patients undergoing liver transplant, 29, 44 which may justify addition of these laboratory assays to standard of difficult. This is consistent with the concept of rebalanced hemostasis, which stands in contrast to prior conceptions of increased bleeding risk in patients with abnormal routine coagulation studies. [17] [18] [19] Hypercoagulability and thrombosis appear to be of even greater concern than bleeding, especially in pediatric recipients, because thrombosis can lead to significant morbidity and mortality. The apparent failure of standard coagulation assays to predict thrombotic events presents an important clinical challenge. Initiation of anticoagulation or antiplatelet therapy-or cessation of measures that might increase thrombotic risk-requires surveillance of the patient's hemostatic
state. An effective strategy for monitoring patients' hemostatic state remains elusive.
